Condition: Superficial Femoral Artery Stenosis · Popliteal Artery Stenosis · Sponsor: Medinol Ltd.
This is a prospective, open label, multicenter, single arm, first in human clinical study. Patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be enrolled. The patients will be treated with the ChampioNIR Stent System. All implanted patients will be followed up at 30 days and 6, 12, 24 and 36 months. The follow-up visits will include patency evaluation by duplex ultrasound
This description comes directly from the study's public registry record.
Brenda Koltun Reuven · 719-331-1638 · brendak@medinol.com
Always discuss trial participation with your own doctor first.
| Piedmont Healthcare, Inc. | Atlanta, Georgia, United States | Not Yet Recruiting |
| Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH | New York, New York, United States | Not Yet Recruiting |
| St Francis Hospital Heart Center | Roslyn, New York, United States | Not Yet Recruiting |
| The Alfred Hospital | Melbourne, Australia | Recruiting |
| Royal Perth Hospital | Perth, Australia | Not Yet Recruiting |
| Royal North Shore Hospital | Sydney, Australia | Recruiting |
| Royal Prince Alfred Hospital | Sydney, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06410313